Reuters logo
BRIEF-Intra-Cellular Therapies provides corporate update on schizophrenia program
2017年5月1日 / 中午12点01分 / 5 个月前

BRIEF-Intra-Cellular Therapies provides corporate update on schizophrenia program

May 1 (Reuters) - Intra-cellular Therapies Inc:

* Intra-Cellular Therapies provides corporate update on schizophrenia program

* Intra-Cellular Therapies - FDA confirmed results of study iti-007-302 do not preclude co from submitting NDA based on efficacy studies conducted to date

* Intra-Cellular Therapies - FDA requested information to confirm nonclinical findings are not indicative of safety risk related to long term exposure in humans

* FDA has not raised any safety concerns regarding study of lumateperone in short term treatment trials in humans

* Intra-Cellular Therapies - if FDA deems responses for nonclinical findings sufficient, to submit NDA for lumateperone for treating schizophrenia by mid-year 2018 Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below